Sakhrani 1992.

Methods	Study design: parallel RCT Study duration: January 1990 to September 1990 Study follow‐up: 1 year
Participants	Country: USA Setting: single centre Inclusion criteria: adult DD kidney transplant recipients Number: treatment group 1 (46); treatment group 2 (37) Mean age ± SD (years): treatment group (43 ± 13); treatment group 2 (42 ± 12) Sex (M/F): treatment group (31/15); treatment group 2 (21/26) Exclusion criteria: not reported
Interventions	Treatment group 1 Minnesota ALG: 10 mg/kg; duration not reported Treatment group 2 Minnesota ALG: 20 mg/kg; duration not reported Immunosuppression (both groups) PRED: dose and dosage not reported AZA: dose and dosage not reported CSA: started when good graft function (good urine output and Cr decrease to < 50% pre transplant); dose and dosage not reported
Outcomes	Graft loss Acute rejection Severe infection Leucopenia
Notes	Death not reported Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgment
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgment
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated how acute rejection was determined
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Kidneys did not function in 4 patients (2 in each group) and 1 patient from each group moved out of the country
Selective reporting (reporting bias)	High risk	Death not reported; results reported as percentages and could not be meta‐analysed
Other bias	Unclear risk	Funding not reported